Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2023

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of March 31, 2023 and December 31, 2022 were as follows:


	March 31, 2023		December 31, 2022
Accrued compensation expenses	$	20,390	$	542,895
Accrued research and development		1,910,749		1,405,536
Accrued professional fees		124,430		83,715
Other accounts payable and accrued expenses		18,413		29,539
Total	$	2,073,982	$	2,061,685